RANGE IMPACT, INC.
RANGE IMPACT, INC. (RNGE): 1 pipeline candidate · ~5 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.8 months
D/E 4.21 · 0% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for RANGE IMPACT, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$46.6M
Cash
$1.3M
Quarterly Burn
$982K
Runway
4.8 mo
Revenue
$915K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| vbx-100 | Preclinical |
Frequently asked questions
How many drug candidates are in RANGE IMPACT, INC.'s pipeline?
RANGE IMPACT, INC. (RNGE) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is RANGE IMPACT, INC.'s lead drug candidate?
RANGE IMPACT, INC.'s most advanced tracked candidate is vbx-100 (Preclinical) for Inflammatory conditions of the gastrointestinal tract.
What is RANGE IMPACT, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, RANGE IMPACT, INC. has approximately 4.8 months of cash runway.
What is RANGE IMPACT, INC.'s market capitalization?
RANGE IMPACT, INC.'s market capitalization is approximately $46.6M.
Who is the CEO of RANGE IMPACT, INC.?
Mr. Michael R. Cavanaugh CPA, J.D. is the chief executive officer of RANGE IMPACT, INC. (RNGE).
Get the full picture on RANGE IMPACT, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.